|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/11/21 Silo Pharma, Inc. 8-K:1,9 1/05/20 2:154K EdgarAgents LLC/FA |
Document/Exhibit Description Pages Size
1: 8-K Current Report HTML 15K
2: EX-10.1 Sponsored Research Agreement by and Between the HTML 81K
Company and the University of Maryland, Baltimore
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 5, 2020
SILO PHARMA, INC.
(Name of registrant in its charter)
| Delaware | 000-54872 | 27-3046338 | ||
| (State or jurisdiction of | (Commission File | (IRS Employer | ||
| incorporation or organization) | Number) | Identification No.) |
560 Sylvan Ave, Suite 3160
(Address of principal executive offices)
(718) 400-9031
(Registrant’s telephone number)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instructions A.2 below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: None.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
C:
Item 1.01. Entry into a Material Definitive Agreement.
On January 5, 2021, Silo Pharma, Inc. (the “Company”) entered into a entered into an investigator-sponsored study agreement (the “Agreement”) with the University of Maryland, Baltimore (“UMB”). The research project is a clinical study to examine a novel peptide-guided drug delivery approach for the treatment of multiple sclerosis. More specifically, the study is designed to evaluate (1) whether MS-1-displaying liposomes can effectively deliver dexamethasone to the CNS and (2) whether MS-1-displaying liposomes are superior to plain liposomes, also known as free drug, in inhibiting the relapses and progression of EAE. Pursuant to the Agreement, the Project Work (as defined in the Agreement) shall commence on March 1, 2021 and will continue until substantial completion, subject to renewal upon mutual written consent of the parties.
The foregoing summary of the Agreement does not purport to be complete and is qualified in its entirety by reference to the Agreement which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is hereby incorporated by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibits
| Exhibit No. | Description | |
| 10.1 | Sponsored Research Agreement by and between the Company and the University of Maryland, Baltimore |
C:
| - C: 1- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SILO PHARMA, INC. | ||
| Date: January 11, 2021 | By: | /s/ Eric Weisblum |
Eric Weisblum, Chief Executive Officer | ||
-2-
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 3/1/21 | ||||
| Filed on: | 1/11/21 | 8-K | ||
| 1/5/21 | 8-K | |||
| For Period end: | 1/5/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/25/24 Silo Pharma, Inc. 10-K 12/31/23 69:6.7M EdgarAgents LLC/FA 3/24/23 Silo Pharma, Inc. 10-K 12/31/22 65:6.8M EdgarAgents LLC/FA 9/20/22 Silo Pharma, Inc. S-1/A 78:9.4M EdgarAgents LLC/FA 9/09/22 Silo Pharma, Inc. S-1/A 9/08/22 80:9.6M EdgarAgents LLC/FA 8/29/22 Silo Pharma, Inc. S-1/A 8/26/22 79:9.5M EdgarAgents LLC/FA 7/25/22 Silo Pharma, Inc. S-1/A 7/22/22 78:9.9M EdgarAgents LLC/FA 3/28/22 Silo Pharma, Inc. 10-K 12/31/21 69:6.2M EdgarAgents LLC/FA 12/07/21 Silo Pharma, Inc. S-1 12/08/21 88:9.2M EdgarAgents LLC/FA 8/13/21 Silo Pharma, Inc. 10-Q 6/30/21 58:4.3M EdgarAgents LLC/FA 5/17/21 Silo Pharma, Inc. 10-Q 3/31/21 57:3.1M EdgarAgents LLC/FA 5/17/21 Silo Pharma, Inc. 10-K/A 12/31/20 69:4.5M EdgarAgents LLC/FA 4/07/21 Silo Pharma, Inc. S-1/A 65:4.4M EdgarAgents LLC/FA 3/29/21 Silo Pharma, Inc. 10-K 12/31/20 69:4.5M EdgarAgents LLC/FA 2/16/21 Silo Pharma, Inc. S-1 73:5.5M EdgarAgents LLC/FA |